Compare GERN & HOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | HOV |
|---|---|---|
| Founded | 1990 | 1959 |
| Country | United States | United States |
| Employees | 258 | 1891 |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 778.7M |
| IPO Year | N/A | N/A |
| Metric | GERN | HOV |
|---|---|---|
| Price | $1.29 | $123.90 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 3 | 2 |
| Target Price | $2.17 | ★ $97.00 |
| AVG Volume (30 Days) | ★ 8.1M | 108.8K |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | $5.96 |
| P/E Ratio | ★ N/A | $17.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $91.52 |
| 52 Week High | $2.01 | $162.06 |
| Indicator | GERN | HOV |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 46.28 |
| Support Level | $1.24 | $119.60 |
| Resistance Level | $1.46 | $127.22 |
| Average True Range (ATR) | 0.07 | 5.70 |
| MACD | -0.02 | -0.79 |
| Stochastic Oscillator | 6.52 | 18.57 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.